gvp posts
FeedPosted Aug 28th 2008 11:24AM by Eric Buscemi (RSS feed)
Filed under: Analyst reports, Analyst upgrades and downgrades, Coca-Cola (KO), Analyst initiations, Gilead Sciences (GILD), China Mobile Limited (CHL)
Analyst upgrades:
- Goldman upgraded BT Group (NYSE: BT) to Buy from Neutral on valuation and improved earnings visibility.
- Soleil upgraded shares of Jo Ann Stores (NYSE: JAS) to Buy from Hold following the company's Q2 upside surprise to reflect strong fundamentals and market share gains. The firm raised Jo Ann's target to $30 from $25.
- Amylin Pharma (NASDAQ: AMLN) was upgraded to Buy from Neutral at Merrill Lynch.
- Energen (NYSE: EGN) was upgraded to Buy from Neutral at UBS.
Analyst downgrades:
- Roth Capital downgraded shares of Warner Chilcott (NASDAQ: WCRX) to Hold from Buy pending patent clarity for the company's lead drug, Loestrin 24 for birth control. The firm lowered their target to $18 from $20.
- JP Morgan cut China Mobile (NYSE: CHL) to Underweight from Overweight as they believe increased competition may limit earnings growth.
- Cantor downgraded shares of Cell Genesys (NASDAQ: CEGE) to Hold from Buy following the termination of the VITAL-2 Phase III clinical trial. The firm also lowered their target to $2 from $10.
- Coca-Cola (NYSE: KO) was lowered to Neutral from Outperform at Credit Suisse.
- Gilead Sciences (NASDAQ: GILD) was downgraded to Equal Weight from Overweight at Lehman.
- Cinemark (NYSE: CNK) was downgraded at BMO Capital to Market Perform from Outperform.
Continue reading Analyst calls: BT, JAS, EGN, CHL, KO, GILD, DWA ...
Five winners of a weak dollar: SBUX, PEP, AAPL
Twitter valuation off by half: NeXt Up Research
Comfort Zone Investing: The unmighty dollar
